Navigation Links
Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs

Can a common virus boost the cancer-killing abilities of existing cancer drugs? A preclinical study presented// at this year’s EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, in Prague, Czech Republic concluded that the answer is “yes.” These findings may lead to more effective treatment options for patients suffering from non-small cell lung cancer (NSCLC), a disease in which malignant (cancer) cells form in the tissues of the lung.

The research focused on work conducted by SAIC-Frederick, Inc., a prime contractor to the National Cancer Institute (NCI). The NCI tested the Respiratory Enteric Orphan virus, or reovirus, a non-disease causing virus in combination with a number of widely used chemotherapy drugs. In general, the combination of reovirus with cisplatin, gemcitabine, mitomycin or vinblastine was found to be more effective against NSCLC cell lines sensitive to anti-cancer drugs than each treatment used on its own. The study used REOLYSIN?, Oncolytics Biotech's proprietary formulation of the human reovirus, that has been demonstrated to replicate specifically in and kill tumor cells with activated Ras pathways (uncontrollable growth signals).

Of particular interest to the researchers, the combination of reovirus and paclitaxel, a common chemotherapy drug, was uniformly synergistic in all six cell lines examined, including in those with high-level resistance to paclitaxel or reovirus. The data suggest that the combination of reovirus and paclitaxel may help in promoting cell-death signaling, resulting in a more efficient and synergistic anti-cancer effect against these cell lines than using each agent on its own.

"Data from the NCI and other investigators examining various co-therapies with REOLYSIN is providing Oncolytics with the rationale for its planned combination clinical trial program," said Dr. Matt Coffey, the Chief Scientific Officer at Oncolytics. "This research suggests that REOLYSIN can be combined with many existing therapies that are currently broadly used in the treatment of cancer patients."

Currently, REOLYSIN is being used in Phase I and Phase I/II human clinical trials in the U.S. and the U.K. and the treatment has recently been approved for use in a Phase II trial in the U.K. for various advanced or metastatic cancers. The treatment appears to be well-tolerated by patients, and anti-tumor effects have been reported in all trials reported on to date. The Company plans to initiate human trials with REOLYSIN and various chemotherapies over the next year.

About 85% of all lung cancers are classified as the non-small cell type. Lung cancer is the leading cause of cancer death for both men and women. More people die of lung cancer than of colon, breast, and prostate cancers combined.

Source-Newswise
SM
'"/>




Related medicine news :

1. Common contraception
2. Common Cold Remedy May Treat SARS
3. Common Plant Triggers Asthma
4. Pain Common in People with MS
5. Common Cold Found to Fight Cancer
6. Bullying – a Common Problem Among Childre
7. Common Medication Errors in Children
8. A Common Cause Of Allergy That Goes Unnoticed
9. Genetic Breakthrough in Common Eye Problem
10. Common Cold Found to Fight Cancer Cells
11. Side Effects Of Some Common Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/21/2017)... Va. (PRWEB) , ... September 21, 2017 , ... ... with a different approach to addiction recovery at a time when Virginia faces ... deaths resulting from drug overdose, a staggering increase of 38 percent from 2015, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... the acquisition of Isle at Kingwood Assisted Living and Memory Care located at ... retirement community with 55 assisted living apartments, 43 memory care apartments and 23 ...
(Date:9/21/2017)... ... September 21, 2017 , ... In ... and Clark College Emeritus Professor of Education Gregory A. Smith examines student privacy ... Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . ...
(Date:9/20/2017)... CHARLOTTE, NC (PRWEB) , ... September 20, 2017 ... ... for Transformation and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) ... newly designed presence offers quick and easy access to essential information that offers ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... one of the Best Places to Work in the Research Triangle for 2017. ... Once nominated, a company had to meet a threshold in employee participation--a percentage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology: